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(57) ABSTRACT 
A novel class of methyl esters of substituted 4-oxo-2-
butenoic acids and their derivatives are disclosed along with 
the surprising use property of these compounds as a bacte-
riostatic agents for humans or non-humans against myco-
bacteria. These compounds include: 4-( 4-Ethoxy-phenyl)-2-
(N'-fiuoren-9-ylidene-hydrazino )-4-oxo-but-2-enoic acid 
methyl ester; 4-( 4-Ethoxy-phenyl)-2-(N'-fiuoren-9-ylidene-
hydrazino )-2-hydroxy-4-oxo-butyric acid methyl ester; 
2-( 4-Bromo-phenylamino )-5,5-dimethyl-4-oxo-hex-2-enoic 
acid methyl ester; A pharmaceutical composition is dis-
closed as well as the method of treating human and non-
humans infected with M. tuberculosis and related mycobac-
teria. 
5 Claims, 1 Drawing Sheet 
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1 
METHYL ESTERS OF SUBSTITUTED 4-
0X0-2-BUTENOIC ACID FOR TREATMENT 
OF TUBERCULOSIS 
This application claims benefit of Ser. No. 60/292,985 5 
filed May 23, 2001. 
FIELD OF THE INVENTION 
2 
sive: a 3 drugs regimen is needed (more than $500/month 
cost per patient). Thus the major problems faced in tuber-
culosis control are poor infrastructures for diagnosis and 
drug supply. The failure of patients to complete therapy as 
well as inappropriate mono-therapy has led to the emergence 
and distribution of strains of Mycobacterium tuberculosis 
resistant to every available chemotherapy (Bloom B R and 
Murray C J L, Science (1992) 257, 1055-1064). Such 
organisms will not remain confined to the Third World or to 
This invention relates to novel methyl esters of substituted 
4-oxo-2-butenoic acid and more particularly to certain moi-
eties of these novel compounds and their close derivatives as 
well as to the methods of their production and to the use of 
these compounds as bacteriostatic agents (a chemical agent 
that stops or inhibits the multiplication of bacteria) for 
humans or non-humans against Mycobacterium 
tuberculosis, and claims the benefit of priority of U.S. 
Provisional Application Ser. No. 60/292,985 filed May 23, 
2001. 
10 the poor and indigent of developed countries. The recent 
documentation of the spread of a single clone of multi-drug 
resistant Mycobacterium tuberculosis (the "W" strain) 
throughout the continental United States and Europe high-
lights the danger of an airborne pathogen in our global 
15 society (Bifani P J, et al., JAMA (1996) 275, 452-457). 
BACKGROUND OF THE INVENTION 20 
The patent literature has numerous disclosures of Hetero-
cyclic oxo-butenoic (crotonic) compounds: They include 
Pamukci (6,232,312) describes crotonic acid derivatives 
(column 22, lines 43-58) for the treatment of colonic 
polyps; 
Jones et al (6,121,450) discloses crotonic acid derivatives 
(column 8, line 34; column 78, line 24 and at example 
340) as steroid modifiers in treating breast cancer (column 
1, lines 55-58); 
25 Kalden, et al (5,334,612) discloses compounds said to be 
useful for treating AIDS including derivatives of carboxy-
lic acid (column 9, line 31) and pyrrolidine (column 7, 
line 24); 
The infectious disease, tuberculosis (TB), is the leading 
cause of death worldwide from a single human pathogen, 
claiming more adult lives than diseases such as acquired 
immunodeficiency syndrome (AIDS), malaria, diarrhea, lep-
rosy and all other tropical diseases combined (Zumla A, 
Grange J. B M J (1998) 316, 1962-1964). The organism 
usually responsible is the tubercle bacillus, Mycobacterium 
tuberculosis (MT), discovered by Robert Koch in 1882. 
However, M. bovis, which infects cattle may also infect man 30 
and M. africanum is a cause of TB in West Africa. 
Furthermore, a number of normally non-pathogenic 
mycobacteria, especially M. avium, M. intracellulare and M. 
scrofulaceum, cause opportunistic infectious disease in 
patients with AIDS (Horne N. 1996. Tuberculosis and other 35 
mycobacteria diseases. In Mansons Tropical Diseases, 20'h 
edn, Cook FEG (ed). WB Saunders: London; 971-1015). 
Pulmonary TB, the most common type of the disease, is 
usually acquired by inhalation of the bacillus from an 
infectious patient and causes irreversible lung destruction. 40 
About one third of the world's population is currently 
infected with M. tuberculosis; 10% of those infected will 
develop clinical diseases, particularly those who also have 
the human immunodeficiency virus (HIV) infection (Zumla 
A, Grange J. B M J (1998) 316, 1962-1964). With the 45 
discovery of effective anti-mycobacteria agents (including 
ethambutol, isoniazid, pyrazinamide, rifampicin and 
streptomycin) and a reduction in poverty, there was a drastic 
decline in the number of TB cases, especially in developed 
nations. However, since the late 1980s, the number of cases 50 
of TB throughout the world has been increasing rapidly 
partly due to the emergence of multi-drug resistant M. 
tuberculosis (C. E. Barry, III, Biochemical Pharmacology 
(1997) 54, 1165-1172). According to the World Health 
Organization (World Health Organization. 1993 92. per 55 
Besra GS, Brennan P J. 1997. J Pharm Pharmacol 49 (Suppl. 
1):25-30.s), it is expected that the annual death rate caused 
Nicolai, et al (6,180,651) discloses many anti-inflammatory 
and analgesic compounds, including adenocarcinoma 
(column 1, line 55), which includes heterocyclic alcohol-
esters (column 11, lines 1-16) and butanoic acid deriva-
tives (many Examples including 47 through 162); 
Brown (6,066,670) describes an anti-viral admixture con-
taining crotonic acid for treating tumors (see Abstract); 
Girard, et al (5,308,852) discloses many compounds includ-
ing butanoic acid derivatives (see Methods B and C of 
schemes II and III) which compounds which are said to 
inhibit tumor metastasis (column 7, line 56 and column 8, 
line 4); 
Harwell, et al (5,580,896) discloses many heterocylic 4-oxo-
2-butenoic acid derivatives (column 13, lines 21-59; also 
in columns 15+, examples 25,26,32,34,40,43-46, 77-79, 
97,99,103,106,), which are useful for inhibiting colorectal 
cancer (Abstract); 
Giordani, et al (6,048,890) discloses 4-oxo-2-butenoic acid 
derivatives said to be useful for treatment of AIDS 
(column 1, line 8 and column 2, line 61; and, 
Yonemeto, et al (6,083,985) recites a number of anti-tumor 
or anti-AIDS agents that include heterocylic butenoic acid 
derivatives. 
For half a century, the most used anti-microbial agents 
referenced above for prophylaxis and treatment of tubercu-
losis since 1952 is isoniazid (isonicotinic acid hydrazide 
[INH]). One of the known complications of anti-tuberculosis 
chemotherapy caused by this drug is liver dysfunction plus 
a great number of other complications. The toxicity of INH 
is also a serious problem frequently resulting in poisoning. 
It is also known to be an acute/chronic hazards since INH is 
an irritant of the skin, eyes, mucous membranes and upper 
respiratory tract. 
by TB will reach an overwhelming 3.5 million people by the 
year 2000. Thus the TB problem requires urgent attention. 
Short course anti-TB regiments initially using at least three 60 
first-line drugs (including isoniazid, rifampicin and 
pyrazinamide) are often not effective due to an increase in 
the number of tuberculosis strains that have become resistant 
It appears from a review of the above that neither the 
heterocyclic oxo-butenoic compounds or the benzoxazine 
heterocyclic compounds of interest are disclosed nor is there 
65 any report of activity against Mycobacterium tuberculosis. 
to current drugs. For example the World Health Organization 
(WHO) recently reported that the death rate of patients with 
multi-drug resistant (MDR) tuberculosis in the US was 
approximately 70%. Current treatment is also very expen-
Consequently, there is a need for an anti-tubercular drug 
for humans or non-humans which mitigates the above men-
US 6,683,110 Bl 
3 
tioned disadvantages of current bacteriostatic agents used as 
drugs against TB bacterium in humans. 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to provide a 5 bacteriostatic agent effective against Mycobacrium tubercu-
losis and other mycobacteria. 
The second object of this invention is to provide a 
bacteriostatic agent that is effective in humans or non-
humans against Mycobacterium tuberculosis and other 
mycobacteria. 
A third object of this invention is to provide a bacterio-
static agent that is effective in humans or non-humans 
against Mycobacterium tuberculosis and other mycobacteria 
which is relatively inexpensive as a drug. 
25 
4 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
As earlier recited this application has been filed in order 
to both disclose new methyl esters of substituted 4-0xo-2-
butenoic acids and to facilitate a fuller understanding of the 
chemical scope of the methyl esters of substituted 4-oxo-2-
butenoic acids. 
OF-12 
The methyl esters can be synthesized according to the 
amination/dehydration steps designated as scheme I. 
Another object of this invention is to provide novel 30 R1~COOCH3 
methyl esters of substituted 4-oxo-2-butenoic acids. II I + 
A preferred embodiment of the invention encompasses a 
class of heterocyclics having the property of a bacteriostatic 
agent against Mycobacterium tuberculosis and other myco- 35 bacterium comprising methyl esters of substituted 4-oxo-2-
butenoic acids and more specifically those derivatives: 4-( 4-
E thoxyp hen y 1)-2-(N'-fluoren-9-ylidenehydrazino )-4-
oxo but-2-enoic acid methyl ester (OF-12); 4-(4-
Ethoxypheny 1)-2-(N'-fluoren-9-ylidenehydrazino )-2-
40 hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-(4-
Bromophenylamino )-5,5-dimethy 1-4-oxohex-2-enoic acid 
methyl ester (OF-15); and the use of each in humans or 
non-humans as therapeutic means for the eradication of 
Mycobacterium tuberculosis and related mycobacteria from 
45 
the humans and nonhumans. 
Further objects and advantages of this invention will be 
apparent from the following detailed description of presently 
preferred embodiments which are illustrated structurally in 
the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 illustrates structurally a chemical compound des-
ignated as OF-12. 
50 
55 
0 OH 
OH 
I 
Ri-C-CH2-C-COOCH3 
II I 
0 NHR2 
R1~COOCH3 
0 NHR2 
2 
More specifically this application is for anti-mycobacteria 
compounds OF-12, OF-13, OF-15, which have been struc-
turally shown in FIGS. 1-3, respectively. To facilitate a full 
understanding of the invention: 
the compound designated as OF-12 is 4-( 4-
Ethoxypheny 1)-2-(N'-fl uoren-9-y lidenehydrazino )-4-
oxobut-2-enoic acid methyl ester; 
the compound designated as OF-13 is 4-( 4-
Ethoxypheny 1)-2-(N'-fl uoren-9-y lidenehydrazino )-2-
hydroxy-4-oxobutyric acid methyl ester; 
the compound designated as OF-15 is 2-( 4-
Bromophenylamino )-5,5-dimethy 1-4-oxohex-2-enoic 
acid methyl ester; FIG. 2 illustrates structurally a chemical compound des-
ignated as OF-13. 
FIG. 3 illustrates structurally a chemical compound des-
ignated as OF-15. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
These compounds are highly active against Mycobacte-
rium tuberculosis and have a very low toxicity, a lethal dose 
50 (LD50) in animals. The percent activity and animal 
60 toxicity for each compound is as follows: OF-12 (81 % and 
LD50>1500 mg/kg), OF-13 (88% and LD50>1500 mg/kg), 
and OF-15 (98% and LD50>1500 mg/kg), 
Before explaining the disclosed embodiments of the 65 
present invention in detail, it is to be understood that the 
invention is not limited in its application to the details of the 
PREPARATION OF (OF-12) 
EXAMPLE 1 
The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9-
ylidene-hydrazino )-4-oxobut-2-enoic acid methyl ester (OF-
US 6,683,110 Bl 
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12). A solution of 5.0 g (0.02 moles) of methyl 4-p-
ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and 3.88 g 
(0.02 moles) of hydrazone fluorenone (2) in 80 mL of 
absolute toluene was refluxed for 3 hr 30 min with a 
Dean-Stark trap (control for the end of the reaction was 5 
carried by 1LC). The solution was cooled and the precipitate 
was filtered and recrystallized from absolute benzene-
hexane (1:1) to give 3.4 g (68% yield) of yellow crystals, mp 
135-137° c. 
Solubility: highly soluble in DMSO, DMFA, 
dichloroethane, acetonitrile; slightly soluble in ethanol, tet-
rachloromethane; insoluble in hexane and water. 
PREPARATION OF (OF-13) 
EXAMPLE 2 
10 
15 
6 
OF-12 The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9- 20 
ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl 
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl 
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and 
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in It is seen from the Scheme 1 that OF-13 is an intermediate 
25 product during the synthesis of OF-12. 80 mL of absolute benzene and absolute toluene (1:1) was 
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of 
the reaction was determined by TLC), cooled and the 
precipitate was filtered and recrystallized from benzene-
diethyl ether-hexane mixture (1:3:2) to give 2.65 g (53% 
yield) of colorless crystals with mp 114-116° C. 
PREPARATION OF OF-15 
30 
Solubility: highly soluble in DMSO, DMFA, 
dichloroethane, acetonitrile, insoluble in hexane. The com-
pound is not stable in solutions and decomposes quickly 
when the solution is heated or stored for a long time with the 35 
formation of OF-12. 
EXAMPLE 3 
The preparation of 2-( 4-Bromophenylamino )-5,5-
dimethyl-4-oxohex-2-enoic acid methyl ester (OF-15). 
The synthesis of (OF-12) and (OF-13) has been desig-
nated as Scheme I and is further illustrated by the prepara-
tion set forth below. 
2 
OH ~COOCH3 
C2HsO~ [ __ _ 
0 NH 
'N 
+ 
cCo 
OF-13 
40 A solution of 5.25 g (0.028 moles) of methyl 2-hydroxy-5, 
5-dimethyl-4oxo-2-hexenoate (1) and 4.85 g (0.028 moles) 
of p-bromoaniline (2) in 30 mL of absolute benzene was 
refluxed for 2 hr with a Dean-Stark trap (Scheme 2). The 
solution was cooled and the resulting precipitate of OF-15 
45 was filtered and recrystallized from methanol to give 8.30 g 
(87%) of yellow crystals with mp of 75-76° C. 
The earlier referenced decarbonylation/transesterification 
reactions designated as Scheme II is readily seen from the 
50 following illustrated synthesis of OF-15. 
CH\ TI 
55 
CH3-C-C-C=C-COOCH3 + 
I I I 
CH3 H OH 
60 
65 
2 
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-continued 
CH\ IT 
CH3-C-C-C=C-COOCH3 
I I I 
CH3 H NH ¢ 
Br 
OF-15 
5 
10 
8 
and the percent inhibition in the presence of extract was 
calculated by the following formulas: 
%GR = G/(with no extract) x lOOo/o 
G/(with the extract) 
o/o/N = 100% - %GR 
GR: Percent growth, G/: Growth index, IN: Percent inhibition 
Animal Toxicity Bioassay. Acute toxicity was studied on 
white mice of both sexes with weight ranging between 
18-26 grams under intraperitoneal injection of 2% solution 
of tested compound in starch (the compound was dissolved 
in starch slime and injected) on the basis of 0.1 ml of 
The bacteriostatic activity against Mycobacterium tuber-
culosis of the novel compounds (as earlier reported) was 
realized by the following procedure. Compound processing: 
Synthetic compounds OF-12, OF-13, OF-15, were each first 
dissolved in 500 ul of dimethylsulfoxide (DMSO) in indi-
vidual beakers and each placed on a rotary shaker overnight. 
Distilled water was added to each to provide a final con-
centration of 10 mg/ml. Each solution was filter-sterilized 
using Becton Dickinson 5 ml sterile syringes and Whatman 
15 solution per 10 g of the animal weight. Each dose was tested 
on the group of 6 animals that were observed during 14 day 
period. (This method was approved by the Pharmacology 
committee of Russian Ministry of Health and has been 
widely used since 1968.) Averaged lethal dose (LD50) of the 
22 um sterile filters. Each of the filtered sterilized synthetic 
test solutions (designated as synthons hereafter) were stored 
at -20 degrees centigrade until used. 
20 compound was computed using results of experiments on 
5-7 groups of animals using the method of Litchfield and 
Wilkinson. (Belenkii M. L. "Elements of quantative deter-
mination of the pharmacological effect," Leningrad, 1963, 
71 pages). 
25 The disclosed invention makes it possible to produce and isolate oxo-heterocyclics, which have the property of a 
bacteriostatic agent toward Mycobacterium tuberculosis and 
other mycobacteria. Culture media and bioassay analytical techniques: BACTEC 12B Mycobacteria also known as Middlebrook 
7H12 Medium was purchased from Becton Dickinson 
(Pittsburgh, Pa.). It contains 7H9 broth base, casein 30 
hydrolysate, bovine serum albumin, catalase and palmitic 
acid labeled with 14C. It is specific for growing mycobac-
teria and is used in conjunction with the BACTEC brand 460 
TB Analyzer. This Middlebrook 7H9 broth base media 
consist of 4 ml of broth mixture included in a sealed bottle. 35 
The culture used in the bioassay was M. tuberculosis (ATCC 
25177). The synthons were added to Bactec 7H12 B+ 
bottled liquid media using Becton Dickinson 1 ml sterile 
syringes to a final concentration of 0.1 mg/ml. To each of 
these Bactec bottles, 100 ul of Bactec 7H12 B+ cultured M. 40 
tuberculosis was inoculated using Becton Dickinson 1 ml 
sterile syringes. Microbial growth activity in this culture 
medium is indicated by the release of 14C02 into the 
atmosphere of the sealed vial following the hydrolysis of 
14C-labeled palmitic acid by the microorganism. The 45 
BACTEC 460 TB Analyzer: The gas in the atmosphere of 
the sealed BACTEC 12B vial is aspirated from the vial via 
a sterile needle attached to a robotic inside the BACTEC 460 
TB Analyzer System. The BACTEC Analyzer operates by 
initially drawing room air through a dust filter, a flush valve, 50 
and an ion chamber transferring all 14C02 into co2 trap 
where it is retained. This process cleans the electrometer and 
leaves it ready to start the next cycle. During the next cycle, 
a pair of 18G needles are heated. A pump produces a partial 
vacuum in the ion chamber used to lower the testing needles 55 
through the rubber septum of the vial being tested. A vacuum 
draws culture gas from the vial to the ion chamber. The 
electrometer measures the very small current that the radio-
active 14C02 produces in the ion chamber. Following 
removal of the radioactive culture gas, fresh 5% C02 is 60 
introduced into the medium headspace every time a vial is 
tested, enhancing the growth of mycobacterium. The current 
measured by the electrometer is amplified and displayed as 
a growth index (GI). The growth index is measured on a 
scale of 0 to 999 and is an indication of microbial growth 65 
activity in the bottle. Usually, a GI of 10 or higher is an 
indication of definite microbial growth. The percent growth, 
ADVANTAGES OF THE DISCOVERY 
This discovery has several advantages. In the background 
there was a short description of one of the most used 
first-line antimicrobial agents for prophylaxis and treatment 
of tuberculosis since 1952. The name of this drug is iso-
niazid (isonicotinic acid hydrazide [INH]). Patients with a 
recently positive protein positive derivative (PPD) skin test 
and a normal chest x-ray routinely are given a 6-9 month 
course of isoniazid. Liver dysfunction is one of known 
complications of antituberculosis chemotherapy caused by 
this drug among a great number of other complications when 
isoniazid is co-administrated with other drugs (W. W. Yew, 
Clinica Chimica Acta 313 (2001) 31-36). 
The toxicity issue is also a serious problem. In the US: A 
surveillance of cases of isoniazid poisoning by the American 
Association of Poison Control Centers from 1985-1993 
revealed a low number of 138 cases in 1985, with no 
fatalities, and a high number of 2656 cases in 1991, with 6 
fatalities. Mortality/Morbidity: Acute ingestion by adults 
with as little as 1.5 g of isoniazid can lead to mild toxicity. 
Ingestion of 6-10 g may be fatal, while ingestion of 15 g is 
usually fatal if not appropriately treated. The overall mor-
tality rate for acute isoniazid toxicity has been estimated to 
be 19%. With current methods of supportive care, however, 
this figure may be high. From 1972-1988, an estimated 152 
fatalities were caused by isoniazid-related hepatitis. The 
overall hepatitis-related death rates among patients using 
isoniazid prophylaxis is approximately 0.001 %. Among 
individuals who complete a full course of prophylaxis, the 
hepatitis-related death rate has been calculated to be 
23.2-57.9/100,000. The mortality rate among individuals 
who develop overt isoniazid-induced hepatitis is 10%. 
Isoniazid is also known to be an acute/chronic hazard. 
This compound is an irritant of the skin, eyes, mucous 
membranes and upper respiratory tract. It can cause harm by 
ingestion, inhalation and skin absorption [Lenga, Robert E. 
The Sigma-Aldrich Library of Chemical Safety Data. Edi-
tion 1. Sigma-Aldrich Corporation. Milwaukee, Wis. 1985. 
p. 1114, #A]. 
US 6,683,110 Bl 
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The acute tox1c1ty of isoniazid is as following: LCLo 
(lowest published lethal concentration) for man is 100 
mg/kg. In animal testing with white mouse LD50 (lethal dose 
50 percent kill) for isoniazid was shown to be 100 mg/kg 
(the same intraperitoneal injection method (Krasil'nikov, I. 
I.; Parfenov, A I.; Strel'nikov, Yu. E.; Smirnova, S. M. 
Radiobiologiya (1973), 13( 4), 551-4), which was used by us 
to determine LD50 dose). All toxicity information about 
isoniazid can also be found on the web site: http://ntp-
server.niehs.nih.gov/htdocs/Chem H&S/NTP Chem5/ 
Radian54-85-3.html 
In addition there are a number of reports in recent 
literature which suggest the importance of developing a new 
treatment to combat strains of the deadly disease tubercu-
losis which have become resistant to current drugs. 
By reference to page 6 first paragraph and in the following 
it is seen that all of the specific compounds of the invention 
exhibit at least 10 times lower acute toxicity compare to 
isoniazid and high activity values. These compounds are 
highly active against Mvcobacterium tuberculosis and have 
a very low toxicity, a lethal dose 50 (LD50) in animals. The 
percent activity and animal toxicity for each compound is as 
follows: OF-12 (81 % and LD50>1500 mg/kg), OF-13 (88% 
and LD50>1500 mg/kg), and OF-15 (98% and LD50>1500 
mg/kg), 
10 
single or multiple doses, once or several times per day. 
Dosages for intraveneous, buccal or sublingual administra-
tion will typically be within the range of from 5-1000 mg 
per single dose as required. In practice the physician will 
5 determine the actual dosing regimen which will be most 
suitable for an individual patient and it will vary with the 
age, weight and response of the particular patient. The above 
dosages are exemplary of the average case but there can be 
individual instances in which higher or lower dosage ranges 
10 may be merited, and such are within the scope of this 
invention. The maximum non-toxic one time administration 
dose for the compound(s) of the invention appears to be 
1500 mg. 
For human use, the compounds of the invention can be 
15 administered alone or jointly, but will generally be admin-
istered in admixture with a pharmaceutical carrier selected 
with regard to the intended route of administration and 
standard pharmaceutical practice. For example, they may be 
administered orally, buccally or sublingually, in the form of 
20 tablets containing excipients such as starch or lactose, or in 
capasules or ovules either alone or in admixture with 
excipients, or in the form of elixirs or suspensions contain-
ing flavouring or colouring agents. The compounds may also 
be injected parenterally, for example intraveneously, 
25 intramuscularly, subcutaneously or intracoronarily. For 
parenteral administration, they are best used in the form of 
a sterile aqueous solution which may contain other 
substances, for example enough salts or glucose to make the 
solution isotonic with blood. 
The methyl esters of substituted 4-oxo-2-butenoic acid 
compounds of the invention, which are unique in their 
anti-tubercular activity, can be used in a pharmaceutical 
composition comprising a non-toxic effective amount of the 
referenced compound or a tautomeric form thereof or a 30 
pharmaceutically acceptable salt thereof or pharmaceuti-
cally acceptable solvate thereof, and a pharmaceutically 
acceptable carrier thereof. 
Thus in a further aspect the invention provides a method 
for the treatment and/or prophylaxis of Mycobacterium 
tuberculosis and related mycobacteria in a human or non-
human which comprises administering an effective, non-
toxic amount of a specific compounds according to the 
invention or a tautomeric form thereof and/or a pharmaceu-
tically acceptable salt thereof and/or a pharmaceutically 
For administration to man in the curative or prophylactic 
treatment of tuberculosis, in vitro dosages of compounds of 35 
the invention will generally be in the range of from 5 to 500 
mg daily for an average adult patient (70 kg). Thus for a 
typical adult patient, individual tablets or capsules contain 
from 2-500 mg of active compound, in a suitable pharma-
ceutically acceptable vehicle or carrier, for administration in 
acceptable solvate thereof, to a tubercular human or non-
human mammal in need thereof. 
Tables 1, 2 and 3 disclose additional methyl esters of 
4-oxo-butenoic acids 
TABLE 1 
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid. 
# Structure 
wherein R1 and R2 are organic substituent groups. 
0 HN....._ 
N 
~ 
Name 
2-(N'-Fluoren-9-ylidene-hydrazino )-4-oxo-4-
p-tolyl-but-2-enoic acid methyl ester 
# Structure 
3 
4 
5 
US 6,683,110 Bl 
11 12 
TABLE 1-continued 
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid. 
wherein R1 and R2 are organic substituent groups. 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
Name 
4-( 4-Ethyl-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
2-(N' -Fluoren-9-ylidene-hydrazino )-4-oxo-4-
o-to l y l-but-2-enoic acid methyl ester 
2-(N' -Fluoren-9-ylidene-hydrazino )-4-oxo-4-
m-tol y l-but-2-enoic acid methyl ester 
4-( 4-Butyl-phenyl)-2-(N' -fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
# Structure 
9 
US 6,683,110 Bl 
13 14 
TABLE 1-continued 
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid. 
wherein R1 and R2 are organic substituent groups. 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
0 HN....._ 
N 
~ 
Name 
4-( 4-tert-Butyl-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
4-(2,4-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
4-(3,4-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
4-(2,5-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
# Structure 
CH3 
13 OCH3 
US 6,683,110 Bl 
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TABLE 1-continued 
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid. 
wherein R1 and R2 are organic substituent groups. 
Name 
2-(N' -Fluoren-9-ylidene-hydrazino )-4-oxo-4-
0 (2, 4, 6-trimeth yl-p hen yl)-but-2-enoic acid methyl ester 
0 
/CH3 
0 HN'-. 
N 
cQ) 
# 
0 
0 
/CH3 
0 HN'-
N 
~ # 
0 
0 
/CH3 
0 HN'-
N 
~ # 
0 HN'-
N 
~ 
2-(N'-Fluoren-9-ylidene-hydrazino )-4-( 4-methoxy-
phenyl)-4-oxo-but-2-enoic acid methyl ester 
4-(2,4-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
4-(3,5-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
US 6,683,110 Bl 
17 
TABLE 1-continued 
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid. 
0 R'do/°" 
0 R1 
wherein R1 and R2 are organic substituent groups. 
18 
# Structure Name 
14 
0 HN....._ 
N 
~ 
4-(2,5-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidene-
hydrazino )-4-oxo-but-2-enoic acid methyl ester 
wherein R1 and R2 are organic substituent groups. 
# 
2 
3 
4 
TABLE II 
Structure H;Cw ~ ,.....-CH3 
H3C 0 
0 
'™)() I# 
Br n,cw ~ ,.....-CH3 
H3C 0 
0 
'™VB' 
n,cw ~ ,.....-CH3 
H3C 0 
0 
'™)() I# 
Cl n,cw ~ ,.....-CH3 
H3C 0 
0 
'™VO 
Name 
2-(2-Bromo-phenylamino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
2-(3-Bromo-phenylamino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
2-(2-Chloro-phenylamino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
2-(3-Chloro-phenylamino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
19 
# Structure 
US 6,683,110 Bl 
TABLE II-continued 
Name 
2-( 4-Chloro-phenylamino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
2-(3-Fluoro-phenylamino )-5 ,5-dimethyl-4-oxo-
hex-2-enoic acid methyl ester 
2-( 4-Fluoro-phenylamino )-5 ,5-dimethyl-4-oxo-
hex-2-enoic acid methyl ester 
2-( 4-Bromo-2-methyl-phenylamino )-5 ,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester 
2-( 4-Bromo-3-methyl-phenylamino )-5 ,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester 
2-( 4-Chloro-2-methyl-phenylamino )-5 ,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester 
20 
# Structure 
# Structure 
2 
3 
21 
US 6,683,110 Bl 
TABLE II-continued 
Name 
2-(2,4-Dichloro-phenylamino )-5 ,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester 
4-(1-Methoxycarbonyl-4,4-dimethyl-3-oxo-
pent-1-enylamino )-benzoic acid ethyl ester 
TABLE 3 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
Name 
4-(1-Methoxycarbonyl-3-oxo-3-phenyl-
propenylamino )-benzoic acid ethyl ester 
2-(1-Methoxycarbonyl-3-oxo-3-phenyl-
propenylamino )-benzoic acid ethyl ester 
2-(3,4-Dichloro-phenylamino )-4-oxo-4-
phenyl-but-2-enoic acid methyl ester 
22 
# Structure 
4 
5 
7 
8 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
0 
0 
/CH3 
0 HN CH3 
o):j'rn, 
I 
C6Hs 
0 
0 
/CH3 
0 HN'-
N 
n,c~ 
# Cl 
0 
0 
/CH3 
0 
0 HN'-
N 
du 
0 HN'-. 
N Br 
dD 
Name 
2-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-
dihydro-lH-pyrazol-4-ylamino )-4-oxo-4-
phenyl-but-2-enoic acid methyl ester 
2-{N' -[ 1-( 4-Chloro-phenyl)-ethylidene ]-
hydrazino }-4-oxo-4-phenyl-but-2-enoic 
acid methyl ester 
2-{N' -[ ( 4-Methoxy-phenyl)-phenyl-
methylene ]-hydrazino }-4-oxo-4-phenyl-
but-2-enoic acid methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-4-oxo-
4-phenyl-but-2-enoic acid methyl ester 
2-{N' -[ (2-Bromo-phenyl)-phenyl-
methylene ]-hydrazino }-4-oxo-4-phenyl-
but-2-enoic acid methyl ester 
24 
# Structure 
11 F 
12 F 
13 F 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
0 HN-..... 
N 
du 
0 HN-..... 
dD 
0 HNX) 
I# 
NC 
0 
0 HN-..... 
du 
Name 
2-(N'-Benzhydrylidene-hydrazino )-4-( 4-
ethoxy-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
4-( 4-Ethoxy-phenyl)-4-oxo-2-[N'-(phenyl-
o-tolyl-methylene )-hydrazino ]-but-2-enoic 
acid methyl ester 
2-(2-Cyano-phenylamino )-4-( 4-fluoro-
phenyl)-4-oxo-but-2-enoic acid methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-4-( 4-
fluoro-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
2-(N'-Di-p-tolylmethylene-hydrazino )-4-( 4-
fluoro-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
26 
# Structure 
16 Cl 
17 Cl 
18 Cl 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
0 HN......_ 
N 
~ 
0 
0 HN~ 
~ Br 
Name 
2-(N'-Fluoren-9-ylidene-hydrazino )-4-( 4-
methoxy-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
2-( 4-Bromo-phenylamino )-4-( 4-ethoxy-
phenyl)-4-oxo-but-2-enoic acid methyl ester 
4-( 4-Chloro-phenyl)-4-oxo-2-(2,4,6-
trimethyl-phenylamino )-but-2-enoic acid 
methyl ester 
2-[3-( 4-Chloro-phenyl)-1-
methoxycarbonyl-3-oxo-propenylamino ]-
benzoic acid ethyl ester 
4-( 4-Chloro-phenyl)-2-{N'-[ 1-( 4-ethoxy-
phenyl)-ethylidene ]-hydrazino }-4-oxo-but-
2-enoic acid methyl ester 
28 
# Structure 
19 Cl 
20 Cl 
21 Br 
22 Br 
23 Br 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
0 HN......_ 
N 
du 
0 HN......_ 
N Br 
dD 
0 HN......_ 
N 
du 
0 HN 
o\5 
Name 
2-(N'-Benzhydrylidene-hydrazino )-4-( 4-
chloro-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
2-{N' -[ (2-Bromo-phenyl)-phenyl-
methylene ]-hydrazino }-4-( 4-chloro-
phenyl)-4-oxo-but-2-enoic acid methyl ester 
4-( 4-Bromo-phenyl)-2-(3,4-dimethyl-
phenylamino )-4-oxo-but-2-enoic acid 
methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-4-( 4-
bromo-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
4-( 4-Bromo-phenyl)-4-oxo-2-[N'-(phenyl-
o-tolyl-methylene )-hydrazino ]-but-2-enoic 
acid methyl ester 
30 
US 6,683,110 Bl 
31 
TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
# Structure 
24 Br 
0 HN~ 
~ 
29 H3CJ:3 ~ 1 /CH3 
H3C' ~ ~ 'o 
0 HN......_ 
N 
\) 
Br 
Name 
4-( 4-Bromo-phenyl)-2-(N' -di-p-
tolylmethylene-hydrazino )-4-oxo-but-2-
enoic acid methyl ester 
2-( 4-Bromo-phenylamino )-4-oxo-4-p-tolyl-
but-2-enoic acid methyl ester 
2-(3,4-Dimethyl-phenylamino )-4-oxo-4-p-
tolyl-but-2-enoic acid methyl ester 
5,5-Dimethyl-4-oxo-2-phenylamino-hex-2-
enoic acid methyl ester 
5,5-Dimethyl-4-oxo-2-p-tolylamino-hex-2-
enoic acid methyl ester 
2-(N'-Benzylidene-hydrazino )-5,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester 
32 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
# Structure 
30 H3C..J:3 ~ 1 /CH3 
H3C' "'lf'" ~ 'o 
0 HN....._ 
N 
»" 
31 H3C..J:3 ~ 1 /CH3 
H3C' "'lf'" ~ 'o 
0 HN....._ 
N 
dD 
32 H3C..J:3 ~ 1 /CH3 
H3C' "'lf'" ~ 'o 
0 HN....._ 
dD 
33 
34 F 
0 HN....._ 
N 
du 
Name 
2-[N'-( 4-Bromo-benzylidene )-hydrazino ]-
5 ,5-dimethyl-4-oxo-hex-2-enoic acid 
methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-5 ,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester 
5,5-Dimethyl-4-oxo-2-[N'-(phenyl-o-tolyl-
methylene )-hydrazino ]-hex-2-enoic acid 
methyl ester 
4-0xo-6-phenyl-2-p-tolylamino-hexa-2,5-
dienoic acid methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-6-( 4-
fluoro-phenyl)-4-oxo-hexa-2,5-dienoic acid 
methyl ester 
34 
# Structure 
US 6,683,110 Bl 
35 
TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
Name 
2-( 4-Bromo-phenylamino )-4-furan-2-yl-4-
oxo-but-2-enoic acid methyl ester 
2-(3,4-Dimethyl-phenylamino )-4-furan-2-
yl-4-oxo-but-2-enoic acid methyl ester 
2-(N'-Benzhydrylidene-hydrazino )-4-furan-
2-yl-4-oxo-but-2-enoic acid methyl ester 
4-Furan-2-yl-4-oxo-2-[N'-(phenyl-o-tolyl-
methylene )-hydrazino ]-but-2-enoic acid 
methyl ester 
2-(N'-Fluoren-9-ylidene-hydrazino )-4-
furan-2-yl-4-oxo-but-2-enoic acid methyl ester 
36 
US 6,683,110 Bl 
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TABLE 3-continued 
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids. 
# Structure Name 
2-(N'-Fluoren-9-ylidene-hydrazino )-4-( 4-
nitro-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
0 HN....._ 
N 
~ 
2-(N'-Benzhydrylidene-hydrazino )-4-( 4-
nitro-phenyl)-4-oxo-but-2-enoic acid 
methyl ester 
0 HN....._ 
du 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. 
We claim: 
1. A compound of a 4-oxo-2-butenoic acid methyl ester 
derivative, having the property of bacteriostatic activity 
against Mycobacteria, the compound consisting of: 
4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9-y lidenehydrazino )-
2-hydroxy-4-oxobutyric acid methyl ester. 
2. A compound of a 4-oxo-2-butenoic acid methyl ester 
derivative having the property of bacteriostatic activity 
against Mycobacteria, the compound consisting of: 
2-( 4-Bromophenylamino )-5 ,5-dimethyl-4-oxohex-2-
enoic acid methyl ester. 
3. A method for the treatment and/or prophylaxis of 
mycobacteria in a human or a non-human which comprises 
administering to said human or non-human in need thereof, 
an effective, non-toxic amount of a compound consisting of 
a 4-oxo-2-butenoic acid methyl ester derivative or a tauto-
meric form thereof and/or a pharmaceutically acceptable salt 
thereof and/or a pharmaceutically acceptable solvate thereof 
which compound is 4-(4-Ethoxyphenyl)-2-(N'-fiuoren-9-
35 ylidenehydrazino )-4-oxobut-2-enoic acid methyl ester. 
4. A method for the treatment and/or prophylaxis of 
mycobacteria in a human or a non-human which comprises 
administering to said human or non-human in need thereof, 
an effective, non-toxic, amount of a compound consisting of 
40 a 4-oxo-2-butenoic acid methyl ester derivative or a tauto-
meric form thereof and/or a pharmaceutically acceptable salt 
thereof and/or a pharmaceutically acceptable solvate thereof 
which compound is 4-(4-Ethoxyphenyl)-2-(N'-fiuoren-9-
ylidenehydrazino )2-hydroxy-4-oxobutyric acid methyl 
ester. 
45 5. A method for the treatment and/or prophylaxis of 
mycobacteria in a human or non-human which comprises 
administering to said human or non-human in need thereof, 
an effective, non-toxic amount of a compound consisting of 
50 
a 4-oxo-2-butenoic acid methyl ester derivative or a tauto-
meric form thereof and/or a pharmaceutically acceptable salt 
thereof and/or a pharmaceutically acceptable solvate thereof 
which compound is 2-( 4-Bromopheny lamina )-5 ,5-
dimethyl-4-oxohex-2-enoic acid methyl ester. 
* * * * * 
